Skip to content

FMT for Alzheimer's disease: what the gut‑brain research shows

If someone you love has Alzheimer's disease, you have probably seen claims that gut health can protect the brain. Some of that research is real, and some of it has been overstated. This page explains what fecal microbiota transplant (FMT) has and hasn't shown in Alzheimer's, in plain language, with every study linked so you can check it yourself. It comes from Resplice Institute, which has FMT centres in Hyderabad and Mumbai.

Illustration of the gut–brain axis in Alzheimer’s diseaseA brain with amyloid plaques connected by the vagus nerve to an intestine populated by gut bacteria.Gut–brain axisAmyloid

Evidence level 2 of 5

Case reports and small studies. See the studies

Can FMT help Alzheimer's disease?

Possibly, but it is not yet proven. In mice, transferring healthy gut microbes reduced amyloid plaques, tau tangles and memory problems. In people, a few published case reports and small studies describe better memory scores after FMT, mostly in patients treated for C. difficile infection. Controlled trials are under way. FMT is not a cure and does not replace care led by your neurologist.

Key points

  • Early human reports used standard memory tests (MMSE, MoCA and CDR) and found scores improved after FMT.
  • By 2025, a systematic review found only five human studies, with 26 patients in total.
  • Most of those patients had FMT for C. difficile infection, so recovering from the infection may explain part of the change.
  • Larger studies are registered, including a 30-patient trial in Shanghai.
  • Outside recognised indications, FMT for Alzheimer's belongs in ethics-approved research, alongside neurologist-led care.

What is fecal microbiota transplant (FMT)?

Fecal microbiota transplant (FMT), also called faecal microbiota transplantation or a stool transplant, moves a complete community of gut bacteria from a carefully screened, healthy donor into a patient’s bowel. The aim is to rebuild a balanced gut microbiome. It is usually given by colonoscopy or enema; some research studies use capsules.

FMT is an established treatment for recurrent C. difficile infection, where gastroenterology guidelines recommend it for suitable adults.2 For Alzheimer’s disease it is still being researched, and it is not an approved treatment.

FMT for Alzheimer's at a glance

StatusInvestigational. Not an approved treatment for Alzheimer’s disease.
Strongest human evidenceCase reports and small studies, 26 patients in five studies by 2025.1
What changed in those reportsMemory and thinking scores (MMSE, MoCA, CDR), mostly after FMT for C. difficile infection.
Biggest uncertaintyNo large randomised trials yet; some benefit may come from recovering from infection.
Standard careNeurologist-led diagnosis, prescribed medicines and support for daily living.
Where FMT fitsWithin ethics-approved research, or for a recognised indication such as recurrent C. difficile infection.

How does the gut affect the brain in Alzheimer's disease?

Your gut holds trillions of microbes that make chemicals, train the immune system and send signals to the brain. Scientists call this two-way link the gut–brain axis. When the gut microbiome loses its balance (dysbiosis), researchers think it may feed the brain inflammation that drives Alzheimer’s disease.

FMT aims to reset this ecosystem by introducing a complete, healthy community of microbes from a screened donor, rather than one or two strains as in a probiotic.

Three routes linking the gut microbiome to the brainDiagram showing three pathways from the gut to the brain: inflammatory signals in the blood, microbial chemicals such as short-chain fatty acids, and the vagus nerve.Inflammationsignals in the bloodMicrobial chemicalsshort-chain fatty acidsVagus nervedirect nerve routeGut microbiome
Three ways the gut microbiome is thought to influence the brain.
  • InflammationIn Alzheimer’s mice, an unhealthy microbiome came with a leaky gut lining and inflammation in both the gut and the rest of the body.3
  • Microbial chemicalsGut bacteria produce short-chain fatty acids and other molecules that influence the brain’s own immune cells.
  • The vagus nerveThis nerve carries signals directly between the gut and the brainstem, in both directions.

How common are Alzheimer's and dementia in India?

India’s first nationally representative dementia study, LASI-DAD, estimated that 7.4% of adults aged 60 and over live with dementia, about 8.8 million people.4 Alzheimer’s disease is the most common cause. As India ages, families are looking for every evidence-based way to protect memory and independence for longer.

About 7 in every 100 Indians aged 60 and over live with dementiaA grid of 100 people with 7 highlighted, representing the 7.4% dementia prevalence among Indians aged 60 and over.
  • About 7 in 100Indians aged 60+ live with dementia (7.4%)
LASI-DAD national estimate.4
8.8 million
Indians aged 60+ living with dementia4
7.4%
of adults aged 60+ have dementia4
Higher
rates in women and in rural areas4

What does the research say about FMT for Alzheimer's?

We rate the evidence on a five-step ladder, from laboratory studies at the bottom to guideline-recommended treatment at the top. Every study below is linked to its source so you can read it yourself.

  1. 5Guideline-recommended careRecurrent C. difficile
  2. 4Multiple randomised trials and meta-analyses
  3. 3Small randomised trials
  4. 2Case reports and small studiesAlzheimer's evidence is here
  5. 1Laboratory and animal research

Level 5 shows where fully proven FMT sits today, for comparison.

Level 5

Guideline-recommended care

FMT is a guideline-recommended treatment for recurrent C. difficile infection

The American Gastroenterological Association’s 2024 guideline recommends fecal microbiota-based therapy to prevent recurrent C. difficile infection in suitable adults. It is shown here as the reference point: this is what fully proven FMT looks like.2

  • Clinical guideline
  • Reference point
Level 4

Multiple randomised trials and meta-analyses

No meta-analyses of randomised trials yet.

Level 3

Small randomised trials

A 2025 review identified one small randomised trial of 20 patients. Further studies are registered, including a 30-patient trial in Shanghai.15

Level 2

Case reports and small studies

An 82-year-old man's memory scores returned to the normal range after FMT

A US case report described a man with Alzheimer’s who received FMT for recurrent C. difficile infection; his symptoms improved and his MMSE score reached 26.6

  • Case report
  • Improvement reported

A 90-year-old woman's scores improved on three cognitive tests

A Korean team reported better MMSE, MoCA and Clinical Dementia Rating results after FMT for severe C. difficile infection.7

  • Case report
  • Improvement reported

Five patients with Alzheimer's dementia: median MMSE rose from 13 to 18

A 2024 preliminary study also found CDR-SB scores fell from 10.0 to 5.5 (lower is better), alongside gut microbiome and lipid-metabolism gene changes.8

  • Small study
  • Improvement reported
Level 1

Laboratory and animal research

Healthy gut microbes reduced plaques and tangles in Alzheimer's mice

Transferring microbiota from healthy mice reduced amyloid plaques, tau tangles, glial activation and memory impairment.3

  • Animal study
  • Benefit seen

A human donor's stool changed Alzheimer's pathology in mice

Stool from a donor carrying the protective APOE ε2 gene reduced amyloid and tau pathology, although some markers of brain inflammation rose.9

  • Animal study
  • Mixed

What the researchers concluded

“…microbiota-mediated intestinal and systemic immune aberrations contribute to the pathogenesis of AD”

Kim et al., Gut, 2020 (mouse study)3

“…clinical evidence remains limited”

Systematic review, Alzheimer's & Dementia, 20251

Our reading of the evidence

The signal is encouraging but early. The human reports involve very few people, most had C. difficile infection at the time, and few had a comparison group, so some of the improvement may reflect recovery from infection. A 2025 systematic review found only five human studies, 26 patients in total, and judged the clinical evidence limited.1 Outside recognised indications, FMT for Alzheimer’s should be used only within an ethics-committee-approved research study. Our specialists can assess whether you have a recognised indication for FMT, such as recurrent C. difficile infection, and go through the evidence with you and your family.

Published case reports: FMT for Alzheimer's

These patients were treated and reported by independent research teams in peer-reviewed journals. They are not Resplice patients, and one person's result does not predict yours.

82-year-old man with Alzheimer's and recurrent C. difficile infection

Published case: Hazan S, J Int Med Res, 2020

Patient
A man with Alzheimer’s dementia (confusion, memory loss and low mood) who was taking memantine and donepezil. His C. difficile infection kept returning after several courses of antibiotics.
Treatment
FMT to clear the recurring infection.
What changed
His Alzheimer’s symptoms improved after FMT. When retested, his MMSE score was 26, which is in the normal range, and four months later he reported continued improvement in memory.
What it can't tell us
This is a single patient with no comparison group. The author described it as the first report of its kind.

90-year-old woman with Alzheimer's dementia and severe C. difficile infection

Published case: Park SH, Curr Med Res Opin, 2021

Patient
A woman with Alzheimer’s dementia, diabetes, high blood pressure and chronic kidney disease, admitted to hospital with diarrhoea and fever.
Treatment
FMT for severe C. difficile infection, with memory testing (MMSE, MoCA and Clinical Dementia Rating) before and after.
What changed
Her scores improved on all three cognitive tests after FMT.
What it can't tell us
One patient and a short follow-up. Recovering from a serious infection can itself sharpen thinking.

Who might FMT be suitable for?

May be appropriate if

  • You have recurrent C. difficile infection, a recognised indication for FMT, whether or not you also have Alzheimer's
  • You are taking part in an ethics-committee-approved research study of FMT in Alzheimer's disease
  • A specialist has assessed the risks and benefits with you and your family, and you have given written informed consent
  • A family member or caregiver can attend appointments and follow-up

Not advised if

  • Your immune system is severely weakened, for example during chemotherapy or on high-dose immunosuppressants
  • Frailty or swallowing problems would make the procedure unsafe
  • You hope to stop prescribed Alzheimer's medicines: FMT is not a replacement
  • You have an untreated infection or a bowel condition that needs hospital care first

What happens at an FMT assessment at Resplice?

Nobody is booked straight in for FMT. A typical pathway has five steps, and you can stop at any point. Your existing doctors are kept informed throughout.

  1. Initial assessment

    A specialist reviews the diagnosis, scans, medicines and gut symptoms with the patient and caregiver, and talks openly about what FMT can and cannot do.

  2. Gut health evaluation

    Blood and stool tests look for infections, inflammation or other problems that need treating first, and help decide whether FMT is appropriate at all.

  3. Microbiome testing and treatment planning

    We map the patient's gut bacteria and record baseline memory scores. You then receive a written plan covering the delivery route, the number of sessions and how progress will be measured.

  4. FMT procedure

    If FMT is appropriate, screened donor microbiota is given by the route chosen for the patient, such as colonoscopy or retention enema.

  5. Follow-up and long-term monitoring

    We repeat memory testing, symptom tracking and microbiome checks at agreed points and share results with the patient's neurologist.

Is FMT safe? Side effects and donor screening

From donor to gut: how FMT works
  1. Healthy donor

    A healthy adult volunteer offers to donate.

  2. Screening

    Health questionnaire plus blood and stool tests.

  3. Stool bank

    Approved samples are processed and stored.

  4. Preparation

    Prepared under laboratory conditions.

  5. Delivery

    Given by colonoscopy, enema or another route.

  6. Engraftment

    Donor microbes settle and grow in the gut.

FMT is generally well tolerated when donors are carefully screened. The most common effects are short-lived bloating, cramps, loose stools or a mild fever. Rare but serious infections have been reported worldwide when donor screening was inadequate, which is why screening matters more than any other step.

People with severely weakened immune systems face higher risks, so your own health is reviewed in detail before FMT is considered, and the benefits, risks and alternatives are explained before you give written consent.

International donor-screening standards include

  • A detailed health, travel and lifestyle questionnaire for every donor
  • Blood tests for infections such as HIV, hepatitis and syphilis
  • Stool tests for C. difficile, disease-causing bacteria, parasites and drug-resistant organisms
  • Repeat testing over time, so that every batch can be traced from donor to patient

Resplice Institute’s FMT service in Hyderabad and Mumbai

Services

Clinical gut-health assessment, microbiome testing, FMT for recognised indications, post-treatment monitoring, and nutrition and lifestyle guidance.

Donor material

Supplied from Resplice Institute's stool bank. Our donor-screening protocol is available on request.

Locations

Hyderabad (Manikonda and Patancheru, Telangana) and Mumbai, Maharashtra.

Charges

Fees depend on the tests and treatment plan, and are given to you in writing before any treatment.

Questions to ask before you consider FMT

Whether you come to us or go elsewhere, these are fair questions to put to any FMT provider. A good clinic will welcome them.

  • Why do you think FMT is appropriate for me, and what is the evidence for my condition?
  • Is this a recognised indication for FMT, or part of an ethics-committee-approved study?
  • How are donors screened, and can I see your screening protocol?
  • Which route will you use, how many sessions will I need, and how do I prepare?
  • Which side effects should I watch for, and who do I call if I feel unwell afterwards?
  • How will we measure whether it has helped, and when?
  • Should any of my current medicines change? (Never stop a medicine on your own.)
  • What is the total cost, including tests and follow-up visits?

Frequently asked questions about FMT for Alzheimer's

Is FMT a cure for Alzheimer's disease?

No. There is currently no cure for Alzheimer’s disease. FMT is being studied as a way to improve the gut–brain environment, and early reports are encouraging, but it has not been proven in large controlled trials. It should only be used alongside standard care.

Is FMT an approved treatment for Alzheimer's?

No. FMT is a guideline-recommended treatment for recurrent C. difficile infection. Its use for Alzheimer’s is investigational, so outside recognised indications it should be used only within ethics-committee-approved research.

How is FMT given to someone with Alzheimer's?

The route depends on the person’s overall health and how comfortably they can go through the procedure. Options include colonoscopy and retention enema. Your specialist will explain which route suits the patient and how to prepare.

Can my parent keep taking donepezil, memantine or other medicines?

Yes. FMT does not replace prescribed medicines, and no one should stop or change Alzheimer’s medication without their neurologist. Antibiotics may need to be timed around FMT, so please bring a full medicine list to the first visit.

How soon could we see a change?

In the published reports, memory scores were rechecked from a few weeks to a few months after FMT. We record baseline scores before treatment so that any change can be measured objectively rather than guessed.

Is FMT safe for elderly patients?

Published case reports include patients in their 80s and 90s, but older patients often have other illnesses and medicines that need careful review. Safety screening of both the patient and the donor is part of every assessment.

Who are stool donors and how are they screened?

Donors are healthy adult volunteers. Under international screening standards, each donor completes a detailed health questionnaire and passes blood and stool tests for infections and drug-resistant bacteria, with testing repeated over time. You are entitled to ask any FMT provider, including us, to explain their donor-screening protocol before treatment.

Where are Resplice Institute's FMT centres?

Resplice Institute’s gut microbiome and FMT service is available in two cities: Hyderabad, at our Manikonda and Patancheru centres in Telangana, and Mumbai, Maharashtra. Assessments, microbiome testing and follow-up can be arranged in either city.

How much does FMT cost in Hyderabad and Mumbai?

Cost depends on the tests you need, the delivery route and the number of sessions in your plan. We give you a written estimate after the first consultation, before any treatment begins.

Contact and appointments

For an appointment with our gut microbiome team, please bring recent scans, test results and a list of current medicines.

Appointment enquiries Call +91 80473 61350 Centres in Hyderabad and Mumbai

Our FMT centres

Hyderabad: Manikonda

Vaishnavione, 3rd Floor, above Vijetha Supermarket, Shivapuri Colony, Manikonda, Hyderabad, Telangana 500089

Hyderabad: Patancheru

RM/6 5-98, beside Rainbow Meadows, Krishna Reddy Pet, Patelguda, Patancheru, Telangana 502319

Mumbai

[Full clinic address and PIN code]
Mumbai, Maharashtra

References

  1. Felippe MFP, et al. Fecal matter transplantation and cognition: a systematic review in Alzheimer’s disease and related disorders. Alzheimers Dement. 2025;21(Suppl 5):e107684. doi.org/10.1002/alz70859_107684
  2. Peery AF, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409–434. doi.org/10.1053/j.gastro.2024.01.008
  3. Kim MS, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020;69(2):283–294. doi.org/10.1136/gutjnl-2018-317431
  4. Lee J, et al. Prevalence of dementia in India: national and state estimates from a nationwide study (LASI-DAD). Alzheimers Dement. 2023;19(7):2898–2912. pubmed.ncbi.nlm.nih.gov/36637034/
  5. Shanghai Tenth People’s Hospital. Clinical safety and efficacy of FMT in the treatment of Alzheimer’s disease. ClinicalTrials.gov identifier NCT06920212. clinicaltrials.gov/study/NCT06920212
  6. Hazan S. Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48(6). doi.org/10.1177/0300060520925930
  7. Park SH, et al. Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report. Curr Med Res Opin. 2021;37(10):1739–1744. doi.org/10.1080/03007995.2021.1957807
  8. Kim JS, et al. Effect of altered gene expression in lipid metabolism on cognitive improvement in patients with Alzheimer’s dementia following fecal microbiota transplantation: a preliminary study. Ther Adv Neurol Disord. 2024;17. doi.org/10.1177/17562864231218181
  9. Marizzoni M, et al. Stools from a human APOEe2 donor reduces amyloid and tau pathology and increases neuroinflammation in a 3xTg AD mouse model. Front Aging Neurosci. 2025. doi.org/10.3389/fnagi.2025.1539067
Call Now Button